ClinicalTrials.gg

Program

zotemtegrast

Also written as “LY4268989” and “MORF-057”.

Its studies are mostly in Colitis, Ulcerative · Crohn Disease, led by Eli Lilly.

Furthest: phase 2, since Mar 10, 20228 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly83 open or runningphase 2since Mar 10, 2022Sep 16, 2020May 2027phase 2 · NCT07186101
  • Named in Eli Lilly’s own pipeline as Zotemtegrast, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 16, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04580745 · 67 enrolled · United States
  2. Mar 10, 2022Phase 2 study in Inflammatory Bowel DiseasesNCT05291689 · 39 enrolled · United States, Poland
  3. Oct 31, 2022Phase 2 study in Inflammatory Bowel DiseasesNCT05611671 · 280 enrolled · United States, Australia, Austria and more
  4. Jan 16, 2024Phase 2 study in Inflammatory Bowel DiseasesNCT06226883 · 385 planned · United States, Australia, Austria and more
  5. May 1, 2025Phase 1 study in HealthyNCT06964776 · 144 enrolled · United States
  6. Sep 16, 2025Phase 2 study in Colitis, UlcerativeNCT07186101 · 252 planned · United States, Austria, Brazil and more
  7. Feb 6, 2026Phase 2 study in Colitis, UlcerativeNCT07415044 · 1,431 planned · United States, Argentina, Brazil and more
  8. Jul 13, 2026Phase 1 study in HealthyNCT07707375 · 50 enrolled · United States

Ahead

  1. May 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07186101
  2. Sep 2028Primary completion: phase 2 study in Inflammatory Bowel DiseasesNCT06226883
  3. Jun 2030Primary completion: phase 2 study in Colitis, UlcerativeNCT07415044

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07707375Healthy · United States1CompletedOct 8, 202650
NCT07415044Colitis, Ulcerative · United States, Argentina, Brazil and more2RecruitingJun 20301,431
NCT07186101Colitis, Ulcerative · United States, Austria, Brazil and more2RecruitingMay 2027252
NCT06964776Healthy · United States1CompletedFeb 17, 2026144
NCT06226883Inflammatory Bowel Diseases · United States, Australia, Austria and more2RecruitingSep 2028385
NCT05611671Inflammatory Bowel Diseases · United States, Australia, Austria and more2CompletedNov 28, 2024280
NCT05291689Inflammatory Bowel Diseases · United States, Poland2CompletedOct 18, 202339
NCT04580745Healthy Volunteers · United States1CompletedMar 31, 202167

How it is read

Names in the registry

  • “LY4268989”, 4 entries
  • “MORF-057”, 4 entries

Codes read as this program: MORF057.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.